Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Forecast 2025-2034

The non-radiographic axial spondyloarthritis (nr-AxSpA) epidemiology forecast suggests that non-radiographic axial spondyloarthritis (nr-AxSpA) and other related conditions typically start in young individuals, especially in people under the age of 45. Approximately 3.2 million Americans are affected by non-radiographic axial spondyloarthritis, according to the Spondylitis Association of America. Additionally, the male-to-female ratio of nr-AxSpA is estimated to be nearly 1:1.

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Forecast Report Coverage

The “Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of non-radiographic axial spondyloarthritis (nr-AxSpA). It projects the future incidence and prevalence rates of non-radiographic axial spondyloarthritis (nr-AxSpA) cases across various populations. The study covers age and type as major determinants of the non-radiographic axial spondyloarthritis (nr-AxSpA) population. The report highlights patterns in the prevalence of non-radiographic axial spondyloarthritis (nr-AxSpA) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on non-radiographic axial spondyloarthritis (nr-AxSpA) epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Understanding: Disease Overview

Non-radiographic axial spondyloarthritis (nr-AxSpA) is a type of inflammatory arthritis that affects the spine and sacroiliac joints (the areas where the spine meets the pelvis). Unlike ankylosing spondylitis, non-radiographic axial spondyloarthritis (nr-AxSpA) doesn’t show any obvious damage to the bones on X-rays. This makes it challenging to diagnose the condition in the early stages.

Common symptoms include chronic lower back pain, especially in the morning or after sitting for long periods, and stiffness in the spine. For the diagnosis of non-radiographic axial spondyloarthritis (nr-AxSpA), a combination of clinical evaluation, MRI scans, and blood tests is performed to check for signs of inflammation or the genetic marker HLA-B27, which is found in many nr-AxSpA patients.

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Perspective

The non-radiographic axial spondyloarthritis (nr-AxSpA) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for non-radiographic axial spondyloarthritis (nr-AxSpA) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for the disease and their trends. The non-radiographic axial spondyloarthritis (nr-AxSpA) detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• According to a 2018 review published in the Expert Review of Clinical Immunology, the lifetime risk of progression from non-radiographic axial spondyloarthritis (nr-AxSpA) to ankylosing spondylitis (AS) is estimated to be 50%.
• Various studies suggest that around 5% to 10% of non-radiographic axial spondyloarthritis (nr-AxSpA) patients experience structural changes in the sacroiliac joints, which are indicative of ankylosing spondylitis (AS), within 2 years.
• The male-to-female ratio in non-radiographic axial spondyloarthritis (nr-AxSpA) is nearly equal, with recent studies indicating that women may have a slightly higher likelihood of developing the condition. Additionally, demographic analyses suggest that around 55%-60% of individuals diagnosed with nr-axSpA are women.
• The Spondylitis Association of America reports that non-radiographic axial spondyloarthritis (nr-AxSpA) often starts in young individuals, particularly those below the age of 45. It is also observed to occur early in life (in juveniles).

Country-wise Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Segment

The non-radiographic axial spondyloarthritis (nr-AxSpA) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of non-radiographic axial spondyloarthritis (nr-AxSpA) varies significantly between countries due to differences in factors such as genetic predisposition (such as the presence of the HLA-B27 gene), ethnic backgrounds, diet, infection rates, lifestyle patterns, healthcare access, the level of awareness about nr-AxSpA, and diagnostic practices, among others. According to the Spondylitis Association of America, about 3.2 million people in the United States are affected by non-radiographic axial spondyloarthritis.

Non-Radiographic Axial Spondyloarthritis (nr-AxSpA): Treatment Overview

The first line of treatment for non-radiographic axial spondyloarthritis (nr-AxSpA) typically involves NSAIDs (nonsteroidal anti-inflammatory drugs) to address pain and inflammation. Corticosteroids are prescribed to reduce swelling in cases where NSAIDs don’t work, while disease-modifying antirheumatic drugs (DMARDs) are recommended for more severe cases.

Biologic treatments such as TNF inhibitors or IL-17 inhibitors are also effective non-radiographic axial spondyloarthritis (nr-AxSpA) therapeutics. These are injections or infusions that target specific parts of the immune system that cause inflammation. Additionally, stretching and strengthening exercises can help manage stiffness and improve movement in the spine and other joints.

Key Questions Answered

• What are the key findings of non-radiographic axial spondyloarthritis (nr-AxSpA) epidemiology in the 8 major markets?
• What will be the total number of patients with non-radiographic axial spondyloarthritis (nr-AxSpA) across the 8 major markets during the forecast period?
• What was the country-wise non-radiographic axial spondyloarthritis (nr-AxSpA) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of non-radiographic axial spondyloarthritis (nr-AxSpA) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of non-radiographic axial spondyloarthritis (nr-AxSpA) during the forecast period of 2025-2034?
• What are the currently available treatments in the non-radiographic axial spondyloarthritis (nr-AxSpA) market?
• What are the disease risks, signs, symptoms, and unmet needs of non-radiographic axial spondyloarthritis (nr-AxSpA)?

Scope of the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of non-radiographic axial spondyloarthritis (nr-AxSpA) based on several factors.
• The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The non-radiographic axial spondyloarthritis (nr-AxSpA) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.